ISB News

New Details on Thyroid Cancer May Lead to More Precise Therapies

3 Bullets:

  • Papillary thyroid cancer represents 80 percent of all thyroid cancer cases.
  • Integrative analysis resulted in the detection of significant molecular alterations not previously reported in the disease.
  • ISB researchers identified microRNAs which may lead to more precise therapy.

By Lisa Iype

Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, accounting for 80 percent of all cases. As part of The Cancer Genome Atlas (TCGA) project, ISB researchers helped to analyze the largest cohort of PTC samples studied to date. The low background mutation density of PTC and the large number of patients in the study enabled the researchers to detect significant molecular alterations that were not associated with the disease before.

Title: Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Publication: Cell
Authors: The Cancer Genome Atlas Research Network
Link: http://www.cell.com/cell/pdf/S0092-8674%2814%2901238-0.pdf

Researchers analyzed DNA sequence, gene expression, microRNA expression, protein expression, and DNA methylation profiles of PTCs to study the disease. ISB researchers played a significant role in exploring associations among these different types of data. They detected potential involvement of certain microRNAs, which are small non-protein-coding RNA molecules that can regulate the activities of other genes, in less differentiated subgroups of PTC, which may lead to more precise surgical and medical therapy.

Studying the disease from a systems perspective demonstrated that the subgroups of PTC differ in their molecular alterations as well as signaling and differentiation characteristics. With this knowledge, the researchers are proposing a refined classification of PTC to reflect these differences and to better inform clinical management of the disease.

Read more about ISB’s role in TCGA.

About Dr. Lisa Iype: Lisa is a bioinformatics scientist in the Shmulevich Lab at ISB. She contributed to the integrative analysis represented in this TCGA Research Network paper.

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.